D. Marucco

Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment

M. Rizzetto, G. di Perri, A. Calcagno, 2012, Therapeutic drug monitoring.

Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.

A. Lazzarin, G. di Perri, A. Calcagno, 2008, The Journal of antimicrobial chemotherapy.

Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment

M. Rizzetto, G. di Perri, A. Calcagno, 2012, Therapeutic drug monitoring.

Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients.

F. D. De Rosa, S. Audagnotto, S. Bonora, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4

M. Rizzetto, A. Calcagno, A. D’Avolio, 2010 .

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.

F. D. De Rosa, G. di Perri, A. Calcagno, 2007, The Journal of antimicrobial chemotherapy.

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.

G. di Perri, A. D’Avolio, M. Siccardi, 2008, The Journal of antimicrobial chemotherapy.

Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment

M. Rizzetto, G. di Perri, A. Calcagno, 2012, Therapeutic drug monitoring.